Literature DB >> 26820362

Mechanisms underlying atrial-selective block of sodium channels by Wenxin Keli: Experimental and theoretical analysis.

Dan Hu1, Hector Barajas-Martínez1, Alexander Burashnikov2, Brian K Panama1, Jonathan M Cordeiro1, Charles Antzelevitch3.   

Abstract

INTRODUCTION: Atrial-selective inhibition of cardiac sodium channel current (INa) and INa-dependent parameters has been shown to contribute to the safe and effective management of atrial fibrillation. The present study was designed to examine the basis for the atrial-selective actions of Wenxin Keli.
METHODS: Whole cell INa was recorded at room temperature in canine atrial and ventricular myocytes. Trains of 40 pulses were elicited over a range of pulse durations and interpulse intervals to determine tonic and use-dependent block. A Markovian model for INa that incorporates interaction of Wenxin Keli with different states of the channel was developed to examine the basis for atrial selectivity of the drug.
RESULTS: Our data indicate that Wenxin Keli does not bind significantly to either closed or open states of the sodium channel, but binds very rapidly to the inactivated state of the channel and dissociates rapidly from the closed state. Action potentials recorded from atrial and ventricular preparations in the presence of 5g/L Wenxin Keli were introduced into the computer model in current clamp mode to simulate the effects on maximum upstroke velocity (Vmax). The model predicted much greater inhibition of Vmax in atrial vs. ventricular cells at rapid stimulation rates.
CONCLUSION: Our findings suggest that atrial selectivity of Wenxin Keli to block INa is due to more negative steady-state inactivation, less negative resting membrane potential, and shorter diastolic intervals in atrial vs. ventricular cells at rapid activation rates. These actions of Wenxin Keli account for its relatively safe and effective suppression of atrial fibrillation.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Antiarrhythmic drugs; Arrhythmias; Atria; Electrophysiology; Pharmacology; Ventricles

Mesh:

Substances:

Year:  2016        PMID: 26820362      PMCID: PMC4758862          DOI: 10.1016/j.ijcard.2016.01.016

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  38 in total

1.  Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone.

Authors:  Alexander Burashnikov; Luiz Belardinelli; Charles Antzelevitch
Journal:  J Pharmacol Exp Ther       Date:  2011-10-17       Impact factor: 4.030

2.  Atrial selective effects of intravenously administered vernakalant in conscious beagle dogs.

Authors:  Jeff Bechard; Marc Pourrier
Journal:  J Cardiovasc Pharmacol       Date:  2011-07       Impact factor: 3.105

3.  How Do Atrial-Selective Drugs Differ From Antiarrhythmic Drugs Currently Used in the Treatment of Atrial Fibrillation?

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  J Atr Fibrillation       Date:  2008

4.  Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation.

Authors:  Alexander Burashnikov; Serge Sicouri; José M Di Diego; Luiz Belardinelli; Charles Antzelevitch
Journal:  J Am Coll Cardiol       Date:  2010-10-05       Impact factor: 24.094

5.  Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart.

Authors:  Kapil Kumar; Bruce D Nearing; Marcelo Carvas; Bruno C G Nascimento; Mariana Acar; Luiz Belardinelli; Richard L Verrier
Journal:  J Cardiovasc Electrophysiol       Date:  2009-02-27

Review 6.  Mechanisms of termination of atrial fibrillation by Class I antiarrhythmic drugs: evidence from clinical, experimental, and mathematical modeling studies.

Authors:  Stanley Nattel; James Kneller; Renqiang Zou; L Joshua Leon
Journal:  J Cardiovasc Electrophysiol       Date:  2003-10

7.  Wenxin Keli attenuates ischemia-induced ventricular arrhythmias in rats: Involvement of L‑type calcium and transient outward potassium currents.

Authors:  Xi Wang; Xin Wang; Yongwei Gu; Teng Wang; Congxin Huang
Journal:  Mol Med Rep       Date:  2012-11-21       Impact factor: 2.952

Review 8.  Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation.

Authors:  Etienne Aliot; Alessandro Capucci; Harry J Crijns; Andreas Goette; Juan Tamargo
Journal:  Europace       Date:  2010-12-07       Impact factor: 5.214

9.  Effects of wenxin keli on the action potential and L-type calcium current in rats with transverse aortic constriction-induced heart failure.

Authors:  Yu Chen; Yang Li; Lili Guo; Wen Chen; Mingjing Zhao; Yonghong Gao; Aiming Wu; Lixia Lou; Jie Wang; Xiaoqiu Liu; Yanwei Xing
Journal:  Evid Based Complement Alternat Med       Date:  2013-11-11       Impact factor: 2.629

Review 10.  The effects of wenxin keli on p-wave dispersion and maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation: a meta-analysis of randomized controlled trials.

Authors:  Yu Chen; Shaoping Nie; Hai Gao; Tao Sun; Xiaoqiu Liu; Fei Teng; Yanhui Xing; Wen Chen; Zhenpeng Zhang; Yonghong Gao; Jie Wang; Yanwei Xing; Hongcai Shang
Journal:  Evid Based Complement Alternat Med       Date:  2013-12-04       Impact factor: 2.629

View more
  11 in total

Review 1.  Mechanisms and Drug Development in Atrial Fibrillation.

Authors:  David Calvo; David Filgueiras-Rama; José Jalife
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

2.  An Overview of Systematic Reviews on the Effectiveness of Wenxin Keli in the Treatment of Atrial Fibrillation.

Authors:  Yuanping Wang; Yuntao Liu; Xia Yan; Dawei Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-30       Impact factor: 2.650

Review 3.  Application of Traditional Chinese Medicine in Treatment of Atrial Fibrillation.

Authors:  Yan Dong; Jiangquan Liao; Kuiwu Yao; Wenrui Jiang; Jie Wang
Journal:  Evid Based Complement Alternat Med       Date:  2017-01-24       Impact factor: 2.629

4.  Shexiang Tongxin dropping pill protects against isoproterenol-induced myocardial ischemia in vivo and in vitro.

Authors:  Jianyong Qi; Wenjun Pan; Yafang Tan; Jiaru Luo; Dancai Fan; Juan Yu; Jiashin Wu; Minzhou Zhang
Journal:  Oncotarget       Date:  2017-11-14

Review 5.  The cardioprotective and antiarrhythmic effects of Nardostachys chinensis in animal and cell experiments.

Authors:  Min Li; Xue Xu; Xinyu Yang; Joey S W Kwong; Hongcai Shang
Journal:  BMC Complement Altern Med       Date:  2017-08-10       Impact factor: 3.659

Review 6.  Therapeutic Effects of Wenxin Keli in Cardiovascular Diseases: An Experimental and Mechanism Overview.

Authors:  Guihua Tian; Yang Sun; Shuo Liu; Chengyu Li; Shiqi Chen; Ruijin Qiu; Xiaoyu Zhang; Youping Li; Min Li; Hongcai Shang
Journal:  Front Pharmacol       Date:  2018-09-05       Impact factor: 5.810

7.  Efficacy of Wenxin Keli Plus Amiodarone versus Amiodarone Monotherapy in Treating Recent-Onset Atrial Fibrillation.

Authors:  Nixiao Zhang; Gary Tse; Shristi Dahal; Yajuan Yang; Mengqi Gong; Calista Zhuo Yi Chan; Enzhao Liu; Gang Xu; Konstantinos P Letsas; Panagiotis Korantzopoulos; Guangping Li; Tong Liu
Journal:  Cardiol Res Pract       Date:  2018-12-04       Impact factor: 1.866

8.  Wenxin Keli Regulates Mitochondrial Oxidative Stress and Homeostasis and Improves Atrial Remodeling in Diabetic Rats.

Authors:  Mengqi Gong; Ming Yuan; Lei Meng; Zhiwei Zhang; Gary Tse; Yungang Zhao; Yue Zhang; Meng Yuan; Xue Liang; Guanwei Fan; Gan-Xin Yan; Guangping Li; Tong Liu
Journal:  Oxid Med Cell Longev       Date:  2020-02-13       Impact factor: 6.543

9.  Chinese natural compound decreases pacemaking of rabbit cardiac sinoatrial cells by targeting second messenger regulation of f-channels.

Authors:  Chiara Piantoni; Manuel Paina; David Molla; Sheng Liu; Giorgia Bertoli; Hongmei Jiang; Yanyan Wang; Yi Wang; Yi Wang; Dario DiFrancesco; Andrea Barbuti; Annalisa Bucchi; Mirko Baruscotti
Journal:  Elife       Date:  2022-03-22       Impact factor: 8.140

10.  Efficacy and safety of Wenxin Keli combined with metoprolol tartrate in the treatment of premature ventricular contractions: A systematic review and meta-analysis.

Authors:  Ping Huang; Yining Luo; Jiaxue Chen; Jingke Xu; Yuanshu Shi; Guoren Chen; Ping Ma
Journal:  Front Cardiovasc Med       Date:  2022-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.